First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstrom's Macroglobulinemia: A systematic review and meta-analysis

Article Oncology

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Christian Buske et al.

Summary: The final analysis of the iNNOVATE study demonstrated that ibrutinib-rituximab maintained sustained efficacy in patients with WM, regardless of MYD88 or CXCR4 mutation status, prior treatment, and key patient characteristics.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia

Steven P. Treon et al.

Summary: In this study, the long-term and final analysis of ibrutinib monotherapy in previously treated patients with WM showed promising results in disease control. Response to treatment was impacted by mutation status of MYD88 and CXCR4, with MYD88(Mut)CXCR4(WT) patients demonstrating higher progression-free survival rates. Treatment with ibrutinib was well-tolerated with manageable adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management

Morie A. Gertz

Summary: WM is a lymphoma with IgM monoclonal protein, diagnosed by presence of clonal lymphoplasmacytic cells and MYD88 gene mutation. Predictive characteristics for outcomes include age, hemoglobin level, platelet count, beta(2) microglobulin, LDH, and monoclonal IgM concentrations. Treatment options include rituximab and bendamustine as preferred induction, with various other agents showing activity in relapsed cases of refractory disease.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Letter Hematology

WhiMSICAL: A global Waldenstrom's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes

Ibrahim Tohidi-Esfahani et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Oncology

Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial

Judith Trotman et al.

Summary: The study demonstrates that single-agent ibrutinib continues to show sustained efficacy and tolerability in patients with heavily pretreated, rituximab-refractory Waldenstrom macroglobulinemia. The response rates deepened over time during the long-term treatment.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia

Gang An et al.

Summary: This study investigated the effect of a BTK inhibitor in Chinese patients with relapsed/refractory WM, demonstrating that zanubrutinib achieved a high response rate across all mutation groups and potentially provides a positive benefit-risk profile for WM treatment.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Letter Hematology